IMPACT-TB: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. Imatinib Mesylate per Oral As a Clinical Therapeutic for TB

Published 2019 View Full Article

Title

IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatinib Mesylate per Oral As a Clinical Therapeutic for TB

Authors

Keywords

Journal

BLOOD

Volume 134, Issue Supplement_1, Pages 1050-1050

Publisher

American Society of Hematology

Online

2019-11-14

DOI

10.1182/blood-2019-130275

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

BLOOD

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.